Recent Progress of Vaccines for Respiratory Syncytial Virus (RSV)
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Influenza Virus Vaccines".
Deadline for manuscript submissions: 31 August 2026
Special Issue Editor
Interests: epidemiology; respiratory disease; global health; respiratory syncytial virus; systematic review; meta-analysis; individual patient data meta-analysis; child health; infectious disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Respiratory Syncytial Virus (RSV) causes significant morbidity and mortality globally. In recent years, there have been notable advancements in RSV vaccine development, including the recent approval of the first RSV vaccines for pregnant women and older adults, as well as a long-acting monoclonal antibody product for infants.
This Special Issue compiles cutting-edge research, clinical trial findings, implementation strategies, and policy discussions centered around the evolving landscape of RSV immunization products. Topics covered include recent clinical trial data, duration of protection, vaccine uptake, and real-world evidence of vaccine effectiveness.
By emphasizing multidisciplinary efforts across clinical trials, basic science, epidemiology, and public health, this issue aims to inform the global response to RSV and its prevention strategies, promoting the integration of new evidence into national immunization programs across various countries. We welcome contributions that address both scientific innovations and the implementation challenges faced in diverse healthcare settings.
Dr. Ting Shi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine update
- vaccine effectiveness
- vaccine safety
- clinical trials
- nirsevimab
- RSV vaccine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
